

Next Science Group  
Level 19, Tower A, The Zenith  
821 Pacific Highway, Chatswood  
NSW 2067  
Australia

## **Next Science® Expands its Board to Support Continued Global Expansion**

**Sydney, NSW:** Next Science is excited to announce the appointment of Aileen Stockburger and Mark Compton (AM) to the Board of the company as Non-Executive Directors. Both bring a wealth of diverse international healthcare experience to the Board, as the company expands the adoption of its Xbio™ Technology and the product applications globally across wound care, surgical infection control and ENT.

Aileen Stockburger is a highly accomplished Strategic Planning and Corporate Transaction Executive with proven expertise backed by an extensive portfolio of successful business development deals. She spent almost 30 years at Johnson & Johnson where she held multiple business development and finance roles in various areas including Medical Devices, Corporate and Consumer. She is the former Worldwide Vice President, Business Development, where she oversaw the group's merger and acquisition activities and led J&J's efforts to acquire Synthes for approximately \$21BN.

Ms. Stockburger has completed numerous M&A, licensing agreements and divestitures across the corporation, with cumulative purchase prices in excess of \$70 BN. These transactions included Pfizer Consumer HealthCare, Aveeno, BabyCenter, OraPharma, DePuy, DePuy Mitek, Kodak Clinical Diagnostics and Neutrogena. Before joining J&J, Ms. Stockburger spent three years at PriceWaterhouse Coopers, where she earned her CPA certification. She received her BS and MBA from the Wharton School, University of Pennsylvania. Ms. Stockburger currently sits on various corporate boards and advises companies in areas of business development and corporate transactions.

Mark Compton (AM) is an experienced Non-Executive Director and CEO in healthcare and life sciences organisations including Australian Securities Exchange (ASX) listed companies. Mark is Chairman and Non-Executive Director of Sonic Healthcare Limited (ASX: SHL), a global medical diagnostics and healthcare organisation. Sonic is a Top 50 ASX listed company. Mark is also a non-executive director on the board of MQ Health and Chairman of St Luke's Care.

He is an Adjunct Professor at Macquarie University where he co-developed and teaches with colleagues a subject in the MBA program on healthcare leadership and innovation. Mark has held various Chief Executive Officer/Managing Director roles including of St Luke's Care, Immune System Therapeutics Limited, Royal Flying Doctor Service of Australia, SciGen Limited and Alpha Healthcare Limited.

He was awarded the Centenary Medal of the Commonwealth of Australia for services to the community; appointed a Knight in the Most Venerable Order of the Hospital of St John of Jerusalem (Order of St John) in 2004; was appointed a Member of the Order of Australia (AM) in January 2010 for services to

# NEXT SCIENCE®

health, hospitals, medical research and St John Ambulance and was promoted to Bailiff Grand Cross of the Order of St John in 2017.

“Next Science counts itself fortunate to have such a strong and diverse Board at this time in our corporate history, as we work to expand the access to our Xbio™ Technology through a strong partnering approach,” said George Savvides, Chairperson of Next Science, “we now consider the board fully formed and are moving from start up to commercialization with the intention to IPO in 2019.”

The board is now fully formed with 6 directors comprising

- George Savvides, Chairperson
  - o Former CEO of Medibank, Sigma Pharmaceuticals, Smith & Nephew.
- Judith Mitchell, CEO & Executive Director
  - o Former President APAC for Depuy Synthes JNJ, exec roles at Cochlear & GE.
- Bruce Hancox, Non-Executive Director
  - o Former Brierley Investments NZ Group CEO & Chairperson.
- Dan Spira, Non-Executive Director
  - o CEO Of iNova Pharmaceuticals, former VP Valeant Pharmaceuticals, JNJ Executive.
- Aileen Stockburger, Non-Executive Director
  - o 30 year career at JNJ including Worldwide VP Business Development, and PWC.
- Mark Compton, Non-Executive Director
  - o Chairperson of ASX 50 Sonic Healthcare, Chairperson pf St Luke’s Care, MQ Health Non-Executive Director.
- Gillian Nairn, Company Secretary

## **About the Next Science Group**

Next Science pioneers innovative, proprietary technologies, including Xbio™, to address the problem of bacterial biofilms. With proven, experienced management and scientific leadership, Next Science and its partners deliver break-through solutions that see beyond the current limits imposed by powerful bacterial colonies. Learn more at [www.nextscience.com](http://www.nextscience.com)

###

### **Inquiries:**

**George Savvides**

Chairperson

+61 2 8607 5124

[info@nextscience.com](mailto:info@nextscience.com)